Hemorrhage stands as the foremost preventable cause of death following trauma, contributing to approximately one-third of all trauma-related fatalities. Whether resulting from a battlefield injury, a car accident, or surgical complications, immediate intervention is crucial when a major blood vessel is compromised.
Researchers at the Korea Advanced Institute of Science and Technology (KAIST) have introduced a groundbreaking solution known as AGCL. This innovative powder converts into a life-saving hydrogel within milliseconds of contact with blood.
The Alchemy of Blood
Blood is a complex mixture, rich in various components, including calcium ions that are vital for heart function. The KAIST team harnessed this internal chemistry, creating a material that reacts with blood rather than merely acting as a physical barrier.
AGCL comprises four key ingredients: alginate (extracted from seaweed), gellan gum, chitosan (derived from shellfish), and a glutaraldehyde crosslinker. Upon application to a bleeding wound, this dry powder reacts almost instantaneously, transforming into a solid adhesive hydrogel. Laboratory tests have shown that AGCL can transition from powder to gel in about one second.
This remarkable material fills irregular wounds effectively, akin to pouring liquid concrete into a rough hole, but with the added advantage of being biocompatible.
The powder boasts an impressive blood absorption ratio of 725%, enabling it to effectively seal wounds while absorbing blood.
A Biological Weld
AGCL has undergone rigorous mechanical stress tests, demonstrating resilience even under simultaneous pulling and twisting forces. It withstood bursting pressure tests at 152.7 mmHg, significantly exceeding the standard human systolic pressure of 120 mmHg.
In essence, AGCL acts as a biological weld, but it offers more than just sealing capability.
Unlike other hemostatic agents that require surgical removal or remain inert in the body, AGCL is regenerative. Its primary components are sugars, allowing the body to recognize it as a supportive structure rather than a foreign object. The chitosan content provides over 99% antibacterial efficacy, which is particularly beneficial in combating hospital-acquired infections and antibiotic-resistant bacteria.
In animal model tests, AGCL not only adhered to wounds but also encouraged tissue regeneration. The treated wounds closed significantly faster than those in control groups, with nearly complete re-epithelialization observed by day 12.
Is it Ready for the Hospital?
While AGCL has shown promising results in mice, the transition to human clinical trials remains a critical step. The material's cost is also a consideration, although its components are abundant and inexpensive.
This innovation signifies a shift towards advanced materials that not only stop bleeding but also utilize the body's properties to facilitate healing. AGCL's stability, tested over two years in open conditions, suggests it could be a valuable resource in various environments, from military settings to remote clinics.
Published in Advanced Functional Materials, AGCL represents a significant leap in trauma care, potentially transforming how we approach emergency medical situations.